Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

The sentinel node biopsy in patients with thick melanoma: outcome analysis from a single-institution database.

Covarelli P, Vedovati MC, Becattini C, Rondelli F, Tomassini GM, Messina S, Noya G, Bistoni G, Simonetti S.

In Vivo. 2011 May-Jun;25(3):439-43.

PMID:
21576420
2.

Prognostic role of sentinel node biopsy in patients with thick melanoma: a meta-analysis.

Rondelli F, Vedovati MC, Becattini C, Tomassini GM, Messina S, Noya G, Simonetti S, Covarelli P.

J Eur Acad Dermatol Venereol. 2012 May;26(5):560-5. doi: 10.1111/j.1468-3083.2011.04109.x. Epub 2011 May 11.

PMID:
21561487
3.

Outcomes for lymph node-positive cutaneous melanoma over two decades.

Martinez SR, Tseng WH, Young SE.

World J Surg. 2011 Jul;35(7):1567-72. doi: 10.1007/s00268-010-0903-8.

4.

Thick primary melanoma has a heterogeneous tumor biology: an institutional series.

Meguerditchian AN, Asubonteng K, Young C, Lema B, Wilding G, Kane JM 3rd.

World J Surg Oncol. 2011 Apr 14;9:40. doi: 10.1186/1477-7819-9-40.

5.

Sentinel lymph node biopsy status is a key parameter to stratify the prognostic heterogeneity of malignant melanoma in high-risk tumors >4.0 mm.

Göppner D, Ulrich J, Pokrywka A, Peters B, Gollnick H, Leverkus M.

Dermatology. 2011 Feb;222(1):59-66. doi: 10.1159/000322495. Epub 2010 Dec 22. Erratum in: Dermatology. 2011;222(4):329.

PMID:
21196701
6.

Final version of 2009 AJCC melanoma staging and classification.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK.

J Clin Oncol. 2009 Dec 20;27(36):6199-206. doi: 10.1200/JCO.2009.23.4799. Epub 2009 Nov 16.

7.

Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?

Gajdos C, Griffith KA, Wong SL, Johnson TM, Chang AE, Cimmino VM, Lowe L, Bradford CR, Rees RS, Sabel MS.

Cancer. 2009 Dec 15;115(24):5752-60. doi: 10.1002/cncr.24660.

8.

Thick melanoma: prognostic value of positive sentinel nodes.

Vermeeren L, van der Ent FW, Sastrowijoto PS, Hulsewé KW.

World J Surg. 2009 Nov;33(11):2464-8. doi: 10.1007/s00268-009-0159-3.

PMID:
19649757
9.

Melanoma.

Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK; NCCN Melanoma Panel.

J Natl Compr Canc Netw. 2009 Mar;7(3):250-75. No abstract available.

PMID:
19401060
10.

Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States.

Bilimoria KY, Balch CM, Wayne JD, Chang DC, Palis BE, Dy SM, Lange JR.

J Clin Oncol. 2009 Apr 10;27(11):1857-63. doi: 10.1200/JCO.2008.18.7567. Epub 2009 Mar 9.

PMID:
19273706
11.

Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.

Gutzmer R, Satzger I, Thoms KM, Völker B, Mitteldorf C, Kapp A, Bertsch HP, Kretschmer L.

J Dtsch Dermatol Ges. 2008 Mar;6(3):198-203. Epub 2007 Dec 17. English, German.

PMID:
18093216
12.

Should all melanoma patients undergo sentinel lymph node biopsy?

Ra JH, McMasters KM, Spitz FR.

Curr Opin Oncol. 2006 Mar;18(2):185-8. Review.

PMID:
16462189
13.

Biology of desmoplastic melanoma: a case-control comparison with other melanomas.

Livestro DP, Muzikansky A, Kaine EM, Flotte TJ, Sober AJ, Mihm MC Jr, Michaelson JS, Cosimi AB, Tanabe KK.

J Clin Oncol. 2005 Sep 20;23(27):6739-46.

PMID:
16170181
14.

Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma.

Jacobs IA, Chang CK, Salti GI.

Am Surg. 2004 Jan;70(1):59-62.

PMID:
14964550
15.

Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it?

Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C.

Ann Surg Oncol. 2003 May;10(4):408-15.

PMID:
12734090
16.

Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy.

Essner R, Chung MH, Bleicher R, Hsueh E, Wanek L, Morton DL.

Ann Surg Oncol. 2002 Oct;9(8):754-61.

PMID:
12374658
17.

Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status.

Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG.

Ann Surg Oncol. 2002 Aug;9(7):637-45.

PMID:
12167577
18.

Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma.

Gershenwald JE, Mansfield PF, Lee JE, Ross MI.

Ann Surg Oncol. 2000 Mar;7(2):160-5.

PMID:
10761797
19.

NCCN melanoma practice guidelines. National Comprehensive Cancer Network.

Houghton A, Coit D, Bloomer W, Buzaid A, Chu D, Eisenburgh B, Guitart J, Johnson T, Miller S, Sener S, Tanabe K, Thompson J, Urist M, Walker M.

Oncology (Williston Park). 1998 Jul;12(7A):153-77. No abstract available.

PMID:
9699216
20.

Surgical management of regional lymph nodes in cutaneous melanoma.

Balch CM.

J Am Acad Dermatol. 1980 Nov;3(5):511-24.

PMID:
7217379

Supplemental Content

Support Center